Medical Lasers

Korean Society for Laser Medicine and Surgery (대한의학레이저학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment of Recurrent Respiratory Papillomatosis Using Laser and Available Adjuvant Therapies

  • Woo, Seung Hoon (Department of Otorhinolaryngology-Head & Neck Surgery, Dankook University College of Medicine) ;
  • Chung, Phil-Sang (Department of Otorhinolaryngology-Head & Neck Surgery, Dankook University College of Medicine) ;
  • Lee, Sang Joon (Department of Otorhinolaryngology-Head & Neck Surgery, Dankook University College of Medicine)
  • Received : 2020.10.21
  • Accepted : 2020.10.31
  • Published : 2020.12.31
⟨ Previous Next ⟩

Abstract

Recurrent respiratory papillomatosis (RRP) is a benign tumor that occurs in the respiratory tract, especially in the larynx. The etiology of RRP is human papillomavirus (HPV). According to the age of occurrence, RRP is divided into childhood-onset and adult-onset types. Generally, childhood-onset RRP shows a high recurrence rate and diffuse involvement in the respiratory tract. Adult-onset RRP is more localized and appears more frequently as a solitary lesion. It may be the result of sexual transmission or the proliferation of latent HPV infections. At present, the treatment of choice for RRP is CO2 laser ablation. In addition, pulse dye laser or KTP (KTiOPO: potassium-titanyl-phosphate) lasers are also used. Non-surgical adjuvant therapies can be applied in cases requiring repetitive surgery or with diffuse extensions. This review will introduce the clinical features of RRP and various treatment options including lasers.

Keywords

References

  1. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008;118:1236-47. https://doi.org/10.1097/MLG.0b013e31816a7135
  2. Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 2004;114(11 Pt 2 Suppl 104):1-23.
  3. Shah KV, Stern WF, Shah FK, Bishai D, Kashima HK. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis J 1998;17:372-6. https://doi.org/10.1097/00006454-199805000-00005
  4. Schraff S, Derkay CS, Burke B, Lawson L. American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg 2004;130:1039-42. https://doi.org/10.1001/archotol.130.9.1039
  5. Dedo HH, Yu KC. CO(2) laser treatment in 244 patients with respiratory papillomas. Laryngoscope 2001;111:1639-44. https://doi.org/10.1097/00005537-200109000-00028
  6. Kashima HK, Kessis T, Mounts P, Shah K. Polymerase chain reaction identification of human papillomavirus DNA in CO2 laser plume from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1991;104:191-5. https://doi.org/10.1177/019459989110400206
  7. Rees CJ, Halum SL, Wijewickrama RC, Koufman JA, Postma GN. Patient tolerance of in-office pulsed dye laser treatments to the upper aerodigestive tract. Otolaryngol Head Neck Surg 2006;134:1023-7. https://doi.org/10.1016/j.otohns.2006.01.019
  8. Van Cutsem E, Snoeck R, Van Ranst M, Fiten P, Opdenakker G, Geboes K, et al. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J Med Virol 1995;45:230-5. https://doi.org/10.1002/jmv.1890450221
  9. Broekema FI, Dikkers FG. Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2008;265:871-9. https://doi.org/10.1007/s00405-008-0658-0
  10. Chadha NK, James AL. Antiviral agents for the treatment of recurrent respiratory papillomatosis: a systematic review of the English-language literature. Otolaryngol Head Neck Surg 2007;136:863-9. https://doi.org/10.1016/j.otohns.2006.09.007
  11. McMurray JS, Connor N, Ford CN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol 2008;117:477-83. https://doi.org/10.1177/000348940811700702
  12. Gillen D. Direct healthcare professional communication regarding serious adverse reactions following off-label use of Vistide [Internet]. Great Abington: Gilead Sciences Limited; 2011. [cited 2011 Jan 12]. Available from: https://www.hpra.ie/docs/default-source/Safety-Notices/dhcp-gilead-12-01-11.pdf?sfvrsn=0.
  13. Derkay CS, Volsky PG, Rosen CA, Pransky SM, McMurray JS, Chadha NK, et al. Current use of intralesional cidofovir for recurrent respiratory papillomatosis. Laryngoscope 2013;123:705-12. https://doi.org/10.1002/lary.23673
  14. Armbruster C, Kreuzer A, Vorbach H, Huber M, Armbruster C. Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b. Eur Respir J 2001;17:830-1. https://doi.org/10.1183/09031936.01.17408300
  15. Essman EJ, Abramson A. Estrogen binding sites on membranes from human laryngeal papilloma. Int J Cancer 1984;33:33-6. https://doi.org/10.1002/ijc.2910330107
  16. Newfield L, Goldsmith A, Bradlow HL, Auborn K. Estrogen metabolism and human papillomavirus-induced tumors of the larynx: chemo-prophylaxis with indole-3-carbinol. Anticancer Res 1993;13:337-41.
  17. Rosen CA, Bryson PC. Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J Voice 2004;18:248-53. https://doi.org/10.1016/j.jvoice.2003.05.005
  18. Leventhal BG, Kashima HK, Weck PW, Mounts P, Whisnant JK, Clark KL, et al. Randomized surgical adjuvant trial of interferon alfa-n1 in recurrent papillomatosis. Arch Otolaryngol Head Neck Surg 1988;114:1163-9. https://doi.org/10.1001/archotol.1988.01860220097032
  19. Healy GB, Gelber RD, Trowbridge AL, Grundfast KM, Ruben RJ, Price KN. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med 1988;319:401-7. https://doi.org/10.1056/NEJM198808183190704
  20. Leventhal BG, Kashima HK, Mounts P, Thurmond L, Chapman S, Buckley S, et al. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1. Papilloma Study Group. N Engl J Med 1991;325:613-7. https://doi.org/10.1056/NEJM199108293250904
  21. Rahbar R, Vargas SO, Folkman J, McGill TJ, Healy GB, Tan X, et al. Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2005;114:289-95. https://doi.org/10.1177/000348940511400407
  22. Zeitels SM, Lopez-Guerra G, Burns JA, Lutch M, Friedman AM, Hillman RE. Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol Suppl 2009;201:1-13.
  23. Maturo S, Hartnick CJ. Use of 532-nm pulsed potassium titanyl phosphate laser and adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children: initial experience. Arch Otolaryngol Head Neck Surg 2010;136:561-5. https://doi.org/10.1001/archoto.2010.81
  24. Zeitels SM, Barbu AM, Landau-Zemer T, Lopez-Guerra G, Burns JA, Friedman AD, et al. Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol 2011;120:627-34. https://doi.org/10.1177/000348941112001001
  25. Endres DR, Bauman NM, Burke D, Smith RJ. Acyclovir in the treatment of recurrent respiratory papillomatosis. A pilot study. Ann Otol Rhinol Laryngol 1994;103(4 Pt 1):301-5. https://doi.org/10.1177/000348949410300407
  26. McGlennen RC, Adams GL, Lewis CM, Faras AJ, Ostrow RS. Pilot trial of ribavirin for the treatment of laryngeal papillomatosis. Head Neck 1993;15:504-12; discussion 512-3. https://doi.org/10.1002/hed.2880150605
  27. Balauff A, Sira J, Pearman K, McKiernan P, Buckels J, Kelly D. Successful ribavirin therapy for life-threatening laryngeal papillomatosis post liver transplantation. Pediatr Transplant 2001;5:142-4. https://doi.org/10.1034/j.1399-3046.2001.005002142.x
  28. Pashley NR. Can mumps vaccine induce remission in recurrent respiratory papilloma? Arch Otolaryngol Head Neck Surg 2002;128:783-6. https://doi.org/10.1001/archotol.128.7.783
  29. Wu R, Coniglio SJ, Chan A, Symons MH, Steinberg BM. Upregulation of Rac1 by epidermal growth factor mediates COX-2 expression in recurrent respiratory papillomas. Mol Med 2007;13:143-50. https://doi.org/10.2119/2007-00005.wu
  30. Shikowitz MJ, Abramson AL, Freeman K, Steinberg BM, Nouri M. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998;10:962-7.
  31. Shikowitz MJ, Abramson AL, Steinberg BM, DeVoti J, Bonagura VR, Mullooly V, et al. Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2005;131:99-105. https://doi.org/10.1001/archotol.131.2.99
  32. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43. https://doi.org/10.1056/NEJMoa061760
  33. McKenna M, Brodsky L. Extraesophageal acid reflux and recurrent respiratory papilloma in children. Int J Pediatr Otorhinolaryngol 2005;69:597-605. https://doi.org/10.1016/j.ijporl.2004.11.021
  34. Holland BW, Koufman JA, Postma GN, McGuirt WF Jr. Laryngopharyngeal reflux and laryngeal web formation in patients with pediatric recurrent respiratory papillomas. Laryngoscope 2002;112:1926-9. https://doi.org/10.1097/00005537-200211000-00003